Can-Fite BioPharma Ltd. (TLV: CANF)
Israel
· Delayed Price · Currency is ILS · Price in ILA
1.700
-0.100 (-5.56%)
Dec 19, 2024, 5:24 PM IDT
Can-Fite BioPharma Revenue
Can-Fite BioPharma had revenue of $158.00K USD in the quarter ending June 30, 2024, a decrease of -19.39%. This brings the company's revenue in the last twelve months to $667.00K, down -15.89% year-over-year. In the year 2023, Can-Fite BioPharma had annual revenue of $743.00K, down -8.27%.
Revenue (ttm)
$667.00K
Revenue Growth
-15.89%
P/S Ratio
11.38
Revenue / Employee
$83.38K
Employees
8
Market Cap
36.79M ILS
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 743.00K | -67.00K | -8.27% |
Dec 31, 2022 | 810.00K | -43.00K | -5.04% |
Dec 31, 2021 | 853.00K | 90.00K | 11.80% |
Dec 31, 2020 | 763.00K | -1.27M | -62.45% |
Dec 31, 2019 | 2.03M | -1.79M | -46.81% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionCan-Fite BioPharma News
- 4 weeks ago - 60 Degrees Pharmaceuticals and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Accesswire
- 5 weeks ago - Can-Fite Achieves Milestone with First Patient Dosing in Pancreatic Cancer Phase IIa Clinical Trial - GlobeNewsWire
- 6 weeks ago - Can-Fite anti-Obesity Drug Namodenoson Received Patent Allowance in Australia - GlobeNewsWire
- 2 months ago - Significant Positive Results from Osteoarthritis Clinical Study in Dogs Treated with Piclidenoson - GlobeNewsWire
- 2 months ago - Can-Fite stock rallies 17% on FDA orphan drug designation - Seeking Alpha
- 2 months ago - FDA Grants Orphan Drug Designation to Can-Fite's Namodenoson for Pancreatic Cancer - GlobeNewsWire
- 3 months ago - Can-Fite: Pancreatic Carcinoma Phase IIa Clinical Study with Namodenoson Received Regulatory Authorization from the Israeli Ministry of Health - GlobeNewsWire
- 4 months ago - Can-Fite BioPharma files to sell 1.77B shares of common stock for holders - Seeking Alpha